Stevens-Johnson Syndrome (SJS)

Stevens-Johnson Syndrome (SJS)

Stevens-Johnson Syndrome (SJS) is a rare but severe immune-mediated disorder characterized by a widespread inflammatory reaction affecting the skin and mucous membranes, including those of the eyes. It typically presents with flu-like symptoms such as fever, sore throat, and cough, followed by the development of painful, blistering skin lesions and mucosal erosions. Involvement of the eyes, known as Stevens-Johnson Syndrome-related ocular involvement (SJS-OI), can lead to serious ocular complications such as conjunctivitis, corneal ulceration, and vision loss.

Diagnosis of Stevens-Johnson Syndrome involves a thorough medical history, physical examination, and evaluation of clinical symptoms. Ophthalmologic assessment is crucial for detecting ocular involvement, which may manifest as redness, tearing, photophobia, and visual disturbances. Confirmation of diagnosis often requires skin biopsy to assess for characteristic histopathologic changes, including epidermal necrosis and dermal lymphocytic infiltration. Prompt recognition and management are essential to prevent complications and minimize long-term sequelae.

The Retyne Infrared Eye Treatment Mask offers a valuable adjunctive therapy for managing ocular symptoms associated with Stevens-Johnson Syndrome. By delivering targeted frequencies known for their anti-inflammatory and tissue-healing properties, the Retyne mask aids in reducing ocular inflammation, promoting epithelial regeneration, and alleviating symptoms such as pain and discomfort. This innovative therapy provides a non-invasive and convenient option for individuals battling the debilitating effects of Stevens-Johnson Syndrome, enhancing their overall treatment outcomes and preserving ocular function.

The Retyne eye treatment mask utilizes a general selection of frequencies (0.07, 0.12, 0.6, 0.87, 2.25, 22.5, 187.5, 396.5, 587.5, 696.5) tailored to address Stevens-Johnson Syndrome. These frequencies have been selected for their proven effectiveness in managing and treating Cornea disorders. Retyne's approach involves converting each frequency into invisible infrared light output, marking a groundbreaking fusion of frequencies with light—a pioneering technology pioneered by Retyne Labs. Inspired by the groundbreaking work of Dr. Rife, who identified healing properties in specific frequencies and utilized light for their transmission, Retyne's innovative method capitalizes on current research on invisible infrared technology and builds upon past studies on light transmission through frequency sources. The result is the Retyne eye Treatment Mask, a convergence of state-of-the-art advancements in the field of visual care.

Moreover, for those utilizing advanced hardware such as the RDPV4, a secondary set of specific frequencies for Stevens-Johnson; (3243: Stevens-Johnson [epidermal necrolysis]: 0.15, 0.22, 3.57, 14.81, 57.63, 291.13, 522.8, 608.11, 771.42, 795.02) is available. The RDPV4 machine offers an expanded range of frequencies, finely calibrated to provide even greater precision for the treatment of this Corneal Disorder. By incorporating this secondary set of frequencies, the RDPV4 elevates the potential therapeutic benefits of the Retyne eye Treatment Mask, catering to individuals seeking advanced solutions for their visual health needs.

A General set group exists at program 810: Corneal Disease: 0.07, 0.32, 0.95, 7.5, 84, 193.93, 237.5, 487.5, 706.21, 946.5
The Advanced Group 3243: Stevens-Johnson [epidermal necrolysis]: 0.15, 0.22, 3.57, 14.81, 57.63, 291.13, 522.8, 608.11, 771.42, 795.02